US govt backs Hikma over ‘skinny label’ rules

Solicitor General urges the US Supreme Court to hear an appeal in its dispute, arguing that a ruling threatens the future of skinny labelling and the availability of lower-cost generics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic

27 June 2024 Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Generics

Hikma ‘skinny’ label does not infringe Amarin patents

6 January 2022 Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More features

Marks & Clerk adds multi-jurisdictional disputes expert

USPTO issues guidance to support patent eligibility declarations

Chest-worn heart monitor tech flatlines in US patent appeal

Novo Nordisk India strategy suffers semaglutide patent setback

FedCirc voids Seagen patent in $41m cancer treatment dispute

Blank Rome expands team with Chicago partner

FisherBroyles grows IP practice with experienced patent attorney

New IP guidance promises to transform the NHS. Will it deliver?

US govt backs Hikma over ‘skinny label’ rules

More on this story

Editor's picks

Editor's picks

More features